Equities

Amicus Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Amicus Therapeutics Inc

Actions
  • Price (USD)14.34
  • Today's Change0.00 / 0.00%
  • Shares traded333.00
  • 1 Year change+45.05%
  • Beta0.4283
Data delayed at least 20 minutes, as of Feb 17 2026 19:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amicus Therapeutics Inc grew revenues 32.29% from 399.36m to 528.30m while net income improved from a loss of 151.58m to a smaller loss of 56.11m.
Gross margin89.77%
Net profit margin-2.35%
Operating margin5.48%
Return on assets-1.70%
Return on equity-6.87%
Return on investment-2.17%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Amicus Therapeutics Inc fell by 33.36m. Cash Flow from Financing totalled 5.12m or 0.97% of revenues. In addition the company used 33.89m for operations while cash used for investing totalled 560.00k.
Cash flow per share-0.021
Price/Cash flow per share--
Book value per share0.7469
Tangible book value per share0.058
More ▼

Balance sheet in USDView more

Amicus Therapeutics Inc has a Debt to Total Capital ratio of 62.98%, a lower figure than the previous year's 217.81%.
Current ratio2.99
Quick ratio2.09
Total debt/total equity1.70
Total debt/total capital0.6298
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.